Lonza sets new mid — term targets, confirms 2026 outlook
Oct 14 (Reuters) — Swiss contract drug manufacturer Lonza set new mid-term targets and confirmed its 2026 outlook on Wednesday ahead of its capital markets day, while saying third-quarter performance was in line with expectations across its business areas. Lonza is seeking to become a pure-play drug manufacturer once i